Skip to search formSkip to main contentSkip to account menu

afelimomab

Known as: MAK 195F 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Immunologic FactorsMonoclonal Antibodies

Narrower (1)

Segard

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
MONARCS: statistical or clinical meaning?
To the Editor: I read with interest the final report of the MONARCS trial by Panacek et al. (1). It seems amazing and hopeful… 
Review
2000
Review
2000
AFELIMOMAB
Tumour necrosis factor‐α (TNF‐α) is well established as a key mediator in the inflammatory response seen in various disease… 
1998
1998
Treatment of severe sepsis in patients with highly elevated IL-6 levels with anti-TNF monoclonal antibody MAK 195F: The Ramses study
1996
1996
Hemostatic parameters in sepsis patients treated with anti-TNF alpha-monoclonal antibodies.
Tumor necrosis factor-alpha (TNF alpha) is a central mediator in the pathogenesis of sepsis. It also interferes with the… 
1995
1995
Effect of postponed treatment with an anti‐tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin‐induced cytokine and neutrophil responses in chimpanzees
TNF is considered to be an intermediate factor in endotoxin‐induced release of other cytokines and endotoxin‐induced neutrophil… 
1995
1995
203 SAFETY AND EFFICACY OF THE MONOCLONAL ANTI-TNF ANTIBODY-FRAGMENT MAK 195F IN PATIENTS WITH SEPSIS AND SEPTIC SHOCK
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)